268 related articles for article (PubMed ID: 21654613)
1. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
Sessa C; Del Conte G
Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
[No Abstract] [Full Text] [Related]
3. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Li GT
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
[No Abstract] [Full Text] [Related]
4. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
6. TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
Samimi G; Ring BZ; Ross DT; Seitz RS; Sutherland RL; O'Brien PM; Hacker NF; Huh WK
Cancer Epidemiol Biomarkers Prev; 2012 Feb; 21(2):273-9. PubMed ID: 22194527
[TBL] [Abstract][Full Text] [Related]
7. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
8. Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
Aust S; Pils S; Polterauer S; Horvat R; Cacsire Castillo-Tong D; Pils D; Dudek G; Schmid B; Speiser P; Reinthaller A; Grimm C
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):518-24. PubMed ID: 23455184
[TBL] [Abstract][Full Text] [Related]
9. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in epithelial ovarian cancer: A population-based study.
Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies in epithelial ovarian cancer.
Kim A; Ueda Y; Naka T; Enomoto T
J Exp Clin Cancer Res; 2012 Feb; 31(1):14. PubMed ID: 22330607
[TBL] [Abstract][Full Text] [Related]
12. Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
Lu CH; Chang YH; Lee WH; Chang Y; Peng CW; Chuang CM;
Chemotherapy; 2016; 61(5):240-8. PubMed ID: 26930357
[TBL] [Abstract][Full Text] [Related]
13. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
14. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
15. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
16. Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer.
Sakarya DK; Yetimalar MH; Ozbasar D
Asian Pac J Cancer Prev; 2015; 16(10):4157-60. PubMed ID: 26028065
[TBL] [Abstract][Full Text] [Related]
17. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
19. Combining targeted therapies in ovarian cancer.
Scambia G; Salutari V; Ferrandina G
Lancet Oncol; 2014 Oct; 15(11):1179-81. PubMed ID: 25218905
[No Abstract] [Full Text] [Related]
20. Trebananib: an alternative anti-angiogenic strategy.
Gourley C
Lancet Oncol; 2014 Jul; 15(8):776-7. PubMed ID: 24950984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
